NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies
Alan P. Venook(University of California, San Francisco), Marian L. Birkeland, Al B. Benson(Northwestern University), Robert J. Morgan(Mayo Clinic), Mary W. Redman(Fred Hutch Cancer Center), Toni K. Choueiri(Harvard University), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Razelle Kurzrock(Medical College of Wisconsin), Vered Stearns(Johns Hopkins University), Joan S. McClure, Gregory P. Kalemkerian(University of Michigan), Donald A. Berry(Berry & Associates (United States)), Christine M. Lovly(Dana-Farber Cancer Institute), Anthony J. Olszanski(Fox Chase Cancer Center), David Ross Camidge(University of Colorado Anschutz Medical Campus), Valerie Guild(AIM at Melanoma Foundation), Amy E. McKee(United States Food and Drug Administration), Robert W. Carlson(National Comprehensive Cancer Network)
Cited by 19
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k